TruScreen Passes CFDA Technical Assessment

NZX and Media Release 24 November, 2017
NZX Limited
WELLINGTON

TruScreen Passes CFDA Technical Assessment for its Second Generation Device
in China

Cervical cancer screening technology company, TruScreen Limited (NZAX: TRU) is pleased to advise
that the CFDA has posted on its website that TruScreen has passed Chinese Food and Drug
Administration (CFDA) technical assessment and its file has proceeded to the final stage of the
approval process. The final culmination of this process would be the formal issuing of the approval
certificate.


ENDS
For more information visit www.truscreen.com or contact:
Martin Dillon
TruScreen Chief Executive Officer
Email: martindillon@truscreen.com
Media Liaison
Jackie Ellis
Email: jackie@ellisandco.co.nz
Phone: +64 27 246 2505


About TruScreen:
TruScreen’s real time cervical cancer technology
utilises a digital wand which is placed on the
surface of the cervix to measure electrical and
optical signals from the surrounding tissue. A
sophisticated proprietary algorithm framework
distinguishes between normal and abnormal
(cancerous and precancerous) tissue to identify
precancerous change, or cervical intraepithelial
neoplasia (CIN). A Single Use Sensor (SUS) is used
for each patient to protect against cross-infection.